POLARAX SYRUP 2mg/5ml

Product Information

Registration Status: Active

POLARAX SYRUP 2mg/5ml is approved to be sold in Singapore with effective from 1989-06-03. It is marketed by SUNWARD PHARMACEUTICAL PTE LTD, with the registration number of SIN02491P.

This product contains Dexchlorpheniramine 2mg/5ml in the form of SYRUP. It is approved for ORAL use.

This product is manufactured by SUNWARD PHARMACEUTICAL PTE LTD in SINGAPORE.

It is a Pharmacy Only Medicine that can be obtained from a pharmacist at a retail pharmacy.

Dexchlorpheniramine

Description

Dexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.

Indication

Dexchlorpheniramine can be used in the treatment of perennial and seasonal allergic rhinitis, vasomotor rhiniti, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, and dermographism.

Mechanism of Action

Competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. Dexchlorpheniramine is the predominant active isomer of chlorpheniramine and is approximately twice as active as the racemic compound.

Pharmacokinetics

Absorption
Oral bioavailability in rats 40.5%
Distribution
321L
Metabolism
Hepatic metabolism. Major metabolism by CYP 2D6 and minor metabolism by 3A4, 2C11 and 2B1.
Elimination

Clearance

9.8L/h

Toxicity

Central nervous system depression

Active Ingredient/Synonyms

Dexchlorpheniramine maleate | Dexchlorpheniramine maleate |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank